{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["carcinoma del colon-retto inoperabile e metastatico","Unresectable and metastatic colorectal cancer","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Carcinoma Del Colon-retto Inoperabile E Metastatico","Unresectable And Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2532389"],"location":["Italy"],"study_start_month":["3"],"keyword":["CAMPTO","FLUOROURACILE TEVA","XELODA","LEVOFOLENE","OXALIPLATINO","Avastin"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI","description":"Primary objectives: Progression free survival","dates":{"creation":"2014-03-15"},"accession":"2532389","cross_references":{"EU Clinical Trials Register":["2013-003244-23"]}}